Cytokinetics, Inc. (CYTK)

[H2R]

omecamtiv mecarbil growing body of evidence

Cytokinetics Reports Positive Data From Trials of Aficamten, Omecamtiv Mecarbil
BY MT Newswires
— 12:27 PM ET 05/23/2022
12:27 PM EDT, 05/23/2022 (MT Newswires) -- Cytokinetics (CYTK) reported positive data Monday regarding investigational drugs aficamten and omecamtiv mecarbil.

The biopharmaceutical company said that aficamten, which is currently being studied in a phase 2 clinical trial, showed sustained and substantial reductions in left ventricular outflow tract gradients, as well as improvements in functional class and symptoms. It also said overall safety and tolerability were favorable.

The company said that data from a phase 3 trial of omecamtiv mecarbil to treat heart failure with reduced ejection fraction was greater than in the overall population, and that blood pressure was not adversely affected with safety similar to placebo.

Cytokinetics (CYTK) said the findings "add to the growing body of evidence demonstrating that patients with clinical features suggestive of high-risk heart failure respond favorably to omecamtiv mecarbil.

"

Best of luck with your investments!